Noticias de NERV_US

Noticias del mercado

Últimas noticias sobre NERV_US — 81 novedades recientes. Análisis, balances, opiniones y cobertura de prensa.

Ticker: NERV_US ✕ 81 resultados
06/04/2026 NERV_US — Stock Titan
Minerva Neurosciences (NASDAQ: NERV) sets 2026 meeting and proposal deadlines
06/04/2026 NERV_US — TipRanks
Minerva Neurosciences Sets 2026 Annual Shareholder Meeting Timeline
06/04/2026 NERV_US — Investing.com
Minerva Neurosciences sets June 2026 date for annual stockholder meeting By Investing.com
06/04/2026 NERV_US — Investing.com
Minerva Neurosciences sets June 2026 date for annual stockholder meeting
03/04/2026 NERV_US — The Globe and Mail
Minerva Neurosciences Appoints New Chief Business Officer, Counsel
03/04/2026 NERV_US — Investing.com ES ← EN
Minerva Neurosciences nombra a Jim O'Connor director comercial Por Investing.com
02/04/2026 NERV_US — GlobeNewswire
Minerva Announces Leadership Transition
02/04/2026 NERV_US — GlobeNewswire
Minerva Announces Leadership Transition
02/04/2026 NERV_US — Stock Titan
Leadership shift at Minerva Neurosciences (NASDAQ: NERV) as O’Connor joins
02/04/2026 NERV_US — Investing.com
Minerva Neurosciences names Jim O’Connor as chief business officer
02/04/2026 NERV_US — NTB Kommunikasjon
Minerva Announces Leadership Transition
02/04/2026 NERV_US — Yahoo Finance
Minerva Announces Leadership Transition
01/04/2026 NERV_US — The Manila Times
Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia
01/04/2026 NERV_US — Stock Titan
[Form 4] Minerva Neurosciences, Inc. Insider Trading Activity
31/03/2026 NERV_US — Intellectia AI
NERV Should I Buy
31/03/2026 NERV_US — GlobeNewswire
Minerva Neurosciences Announces First Patient Screened in
31/03/2026 NERV_US — Stock Titan
No approved drug exists for these schizophrenia symptoms; Minerva starts Phase 3
31/03/2026 NERV_US — Seeking Alpha
Minerva Neurosciences: Plodding Ahead After Another Roluperidone Delay In Negative Symptoms Of Schizophrenia
31/03/2026 NERV_US — Stock Titan
NERV (NASDAQ: NERV) Form 144 shows 156,410-share sale, 650,000 offered
31/03/2026 NERV_US — NTB Kommunikasjon
Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia

Página 3 de 5

keyboard_arrow_up